Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
77
VRNA Quote, Financials, Valuation and Earnings
Last price:
$104.75
Seasonality move
:
15.68%
Day range:
$104.71 - $104.91
52-week range:
$18.51 - $104.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
39.35x
Volume:
6.9M
Avg. volume:
5.1M
1-year change:
370.53%
Market cap:
$8.9B
Revenue:
$42.3M
EPS (TTM):
-$2.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$92.4M | $0.09 | 2034.1% | -97.73% | $106.22 |
|
AUTL
Autolus Therapeutics PLC
|
$12.9M | -$0.23 | -80.39% | -10.73% | $9.86 |
|
BCYC
Bicycle Therapeutics PLC
|
$9.4M | -$0.93 | 0.73% | -20.58% | $26.27 |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.01 | -100% | -87.66% | $7.32 |
|
MRK
Merck &
|
$15.9B | $2.03 | 2.66% | 96.96% | $101.79 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$104.74 | $106.22 | $8.9B | -- | $0.00 | 0% | -- |
|
AUTL
Autolus Therapeutics PLC
|
$2.44 | $9.86 | $649.4M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$7.78 | $26.27 | $538.8M | -- | $0.00 | 0% | 19.61x |
|
MREO
Mereo BioPharma Group PLC
|
$1.75 | $7.32 | $278.3M | -- | $0.00 | 0% | -- |
|
MRK
Merck &
|
$82.43 | $101.79 | $207B | 12.00x | $0.81 | 3.88% | 3.27x |
|
NCNA
NuCana PLC
|
$0.05 | $104.00 | $304.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
51.62% | 1.047 | 4.47% | 8.30x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.256 | -- | 8.74x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.061 | -- | 14.57x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.029 | -- | -- |
|
MRK
Merck &
|
41.89% | 0.213 | 16.34% | 0.80x |
|
NCNA
NuCana PLC
|
-- | -1.015 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$72.8M | -$10.3M | -51.07% | -85.84% | -8.34% | -$12.1M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$70M | -27.79% | -28.27% | -619.32% | -$87M |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$11M | -- | -- | -- | -$8.6M |
|
MRK
Merck &
|
$12.1B | $5.9B | 21.5% | 39.02% | 40.03% | $1.2B |
|
NCNA
NuCana PLC
|
-- | -$3.5M | -- | -- | -- | -$4M |
Verona Pharma PLC vs. Competitors
-
Which has Higher Returns VRNA or AUTL?
Autolus Therapeutics PLC has a net margin of -21.4% compared to Verona Pharma PLC's net margin of -781.13%. Verona Pharma PLC's return on equity of -85.84% beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About VRNA or AUTL?
Verona Pharma PLC has a consensus price target of $106.22, signalling upside risk potential of 1.42%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 303.92%. Given that Autolus Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Autolus Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC1 10 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is VRNA or AUTL More Risky?
Verona Pharma PLC has a beta of 0.240, which suggesting that the stock is 76.016% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.299%.
-
Which is a Better Dividend Stock VRNA or AUTL?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or AUTL?
Verona Pharma PLC quarterly revenues are $76.3M, which are larger than Autolus Therapeutics PLC quarterly revenues of $9M. Verona Pharma PLC's net income of -$16.3M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns VRNA or BCYC?
Bicycle Therapeutics PLC has a net margin of -21.4% compared to Verona Pharma PLC's net margin of -608.94%. Verona Pharma PLC's return on equity of -85.84% beat Bicycle Therapeutics PLC's return on equity of -28.27%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M -
What do Analysts Say About VRNA or BCYC?
Verona Pharma PLC has a consensus price target of $106.22, signalling upside risk potential of 1.42%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $26.27 which suggests that it could grow by 237.7%. Given that Bicycle Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC1 10 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is VRNA or BCYC More Risky?
Verona Pharma PLC has a beta of 0.240, which suggesting that the stock is 76.016% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.784%.
-
Which is a Better Dividend Stock VRNA or BCYC?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or BCYC?
Verona Pharma PLC quarterly revenues are $76.3M, which are larger than Bicycle Therapeutics PLC quarterly revenues of $10M. Verona Pharma PLC's net income of -$16.3M is higher than Bicycle Therapeutics PLC's net income of -$60.8M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 19.61x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M
-
Which has Higher Returns VRNA or MREO?
Mereo BioPharma Group PLC has a net margin of -21.4% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -85.84% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About VRNA or MREO?
Verona Pharma PLC has a consensus price target of $106.22, signalling upside risk potential of 1.42%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.32 which suggests that it could grow by 318.54%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC1 10 0 MREOMereo BioPharma Group PLC6 0 0 -
Is VRNA or MREO More Risky?
Verona Pharma PLC has a beta of 0.240, which suggesting that the stock is 76.016% less volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.683%.
-
Which is a Better Dividend Stock VRNA or MREO?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or MREO?
Verona Pharma PLC quarterly revenues are $76.3M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Verona Pharma PLC's net income of -$16.3M is lower than Mereo BioPharma Group PLC's net income of -$12.9M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M MREOMereo BioPharma Group PLC-- -- -- -$12.9M
-
Which has Higher Returns VRNA or MRK?
Merck & has a net margin of -21.4% compared to Verona Pharma PLC's net margin of 32.71%. Verona Pharma PLC's return on equity of -85.84% beat Merck &'s return on equity of 39.02%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M MRKMerck &77.98% $2.01 $83.2B -
What do Analysts Say About VRNA or MRK?
Verona Pharma PLC has a consensus price target of $106.22, signalling upside risk potential of 1.42%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Merck & has higher upside potential than Verona Pharma PLC, analysts believe Merck & is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC1 10 0 MRKMerck &12 11 0 -
Is VRNA or MRK More Risky?
Verona Pharma PLC has a beta of 0.240, which suggesting that the stock is 76.016% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.
-
Which is a Better Dividend Stock VRNA or MRK?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios VRNA or MRK?
Verona Pharma PLC quarterly revenues are $76.3M, which are smaller than Merck & quarterly revenues of $15.5B. Verona Pharma PLC's net income of -$16.3M is lower than Merck &'s net income of $5.1B. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M MRKMerck &3.27x 12.00x $15.5B $5.1B
-
Which has Higher Returns VRNA or NCNA?
NuCana PLC has a net margin of -21.4% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -85.84% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M NCNANuCana PLC-- -$0.63 -- -
What do Analysts Say About VRNA or NCNA?
Verona Pharma PLC has a consensus price target of $106.22, signalling upside risk potential of 1.42%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 207071.32%. Given that NuCana PLC has higher upside potential than Verona Pharma PLC, analysts believe NuCana PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC1 10 0 NCNANuCana PLC0 1 0 -
Is VRNA or NCNA More Risky?
Verona Pharma PLC has a beta of 0.240, which suggesting that the stock is 76.016% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.
-
Which is a Better Dividend Stock VRNA or NCNA?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or NCNA?
Verona Pharma PLC quarterly revenues are $76.3M, which are larger than NuCana PLC quarterly revenues of --. Verona Pharma PLC's net income of -$16.3M is lower than NuCana PLC's net income of -$3.1M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M NCNANuCana PLC-- -- -- -$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
